---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-029318"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:26:59.518497+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx reports preliminary Q4 GAAP net loss of $7.2M, extends audited financials deadline

## Summary
- GAAP net loss for Q4 2023 was $7.2M vs $0.3M loss in Q4 2022; FY2023 net loss $20.6M vs $11.4M.
- Adjusted EBITDA for Q4 2023 was $5.8M vs $3.9M; FY2023 Adjusted EBITDA $3.6M vs $5.5M.
- Recorded $6.7M asset impairment and $2.1M loss on disposal of business in Q4 2023.
- Lenders extended deadline for audited FY2023 financial statements to April 15, 2024.

## SEC filing metadata
- accession: 0001213900-24-029318
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/ea0203141-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-029318
- JSON: https://secwatch.observer/filing/0001213900-24-029318.json
- Plain text: https://secwatch.observer/filing/0001213900-24-029318.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported preliminary financial results for the three and twelve months ended December 31, 2023.
  - Period: the three and twelve months ended December 31, 2023
  - Result: preliminary results
  source text: On March 28, 2024, the Company held a conference call to discuss preliminary, unaudited results for the fourth quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm
- Material Agreements
  OptimizeRx Corp amended Financing Agreement with Blue Torch Finance, LLC valued at Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20 (effective 2024-03-29).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Blue Torch Finance, LLC
  - Value: Amendment No. 1 to the Financing Agreement extended the Financial Reporting Due Date to April 15, 20
  - Effective: 2024-03-29
  source text: On March 29, 2024, OptimizeRx Corporation (the “Company”) entered into Amendment No. 1 to the Financing Agreement (the “Amendment”) which amends the Financing Agreement, dated as of October 11, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “Financing Agreement”) between the Company, the lenders from time to time party thereto (the “Lenders”) and Blue Torch Finance, LLC, a Delaware limited liability company (“Blue Torch”), as collateral agent and administrative agent for the Lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390024029318/0001213900-24-029318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.